Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BAFNAPH.NS
HoldPremium GrowerBafna Pharmaceuticals Limited · Healthcare · India · $77M · Avg Vol: $98K/d
55
StockRankGet insider-trade alerts
Q
52
V
18
M
80
P/E (TTM)
91.7x
ROE
11.5%
D/E
0.4x
Dividend %
—
COMPANY DESCRIPTION
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. The company offers its products in various dosage forms, including tablets, capsules, and solid orals.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 1.2B | 1.5B | 1.5B | 1.5B | 9.3% | 1.4B |
| EPS (INR) | 4.79 | 3.11 | 1.76 | 4.69 | -0.7% | 3.30 |
| Shares | 23.7M | 23.7M | 23.7M | 23.7M | 0.0% | 23.7M |
| Debt | 229.2M | 243.9M | 282.0M | 374.3M | 17.8% | 375.6M |
| Equity | 734.5M | 808.4M | 848.1M | 961.5M | 9.4% | — |
| Op CF | 49.5M | 94.8M | 221.4M | 153.7M | 45.9% | 154.2M |
| Inv CF | -74.9M | -150.5M | -211.6M | -224.0M | — | — |
| Fin CF | 101.8M | -8.5M | 10.6M | 56.2M | — | — |
Loading 1Y...
PRICE (1Y)+19.3%
SMA 50SMA 200
Close
$3.16
RSI (14)
74.5
52W High
$3.34
From 52W High
0.9%
SCORE BREAKDOWN
Quality
52
ROIC
9.6%70.3
ROE
11.5%74.9
GP/Assets
25.6%55.5
Op. Margin
-3.4%30.5
FCF/Assets
-5.4%34.6
Piotroski
668.8
Int. Cover
3.1x46.2
D/E Ratio
0.39x34.9
Current Ratio
1.57x28.2
Value
18
P/E (TTM)
91.7x10.3
EV/EBITDA
69.2x7.9
P/FCF
—N/A
P/B
7.4x17.2
P/S
5.0x41.4
Div Yield
—N/A
Momentum
80
52W High %
95%93.9
RS 6M
186%99.2
SMA 50/200
1.53x98.2
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
-98%0.6
FUNDAMENTALS
Market Cap
$77M
P/E (Forward)
—
Gross Margin
31.6%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BAFNAPH.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BAFNAPH.NS | Bafna Pharmaceuticals Limited(you) | $77M | 55 | Hold |
| KILITCH.NS | Kilitch Drugs (India) Limited | $69M | 58 | Hold |
| ZIMLAB.NS | ZIM Laboratories Limited | $73M | 67 | Buy |
| BAJAJHCARE.NS | Bajaj HealthCare Limited | $120M | 60 | Hold |
| AMRUTANJAN.NS | Amrutanjan Health Care Limited | $153M | 54 | Hold |
| THEMISMED.NS | Themis Medicare Limited | $129M | 63 | Hold |
| WANBURY.NS | Wanbury Limited | $91M | 70 | Buy |
| SIGACHI.NS | Sigachi Industries Limited | $140M | 43 | Hold |
| AMANTA.NS | Amanta Healthcare Limited | $83M | 82 | Strong Buy |
| INDOCO.NS | Indoco Remedies Limited | $237M | 63 | Hold |
Peer medians: ROE 11.9% · P/E 42.5x · Gross margin 59.4%